Text Size

a Clinical Study.the Effect of Addition of Insoluble Antibacterial Nanoparticles(IABN) in Resin Base Provisional Cement

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2009 by Hadassah Medical Organization.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00502606
First received: July 16, 2007
Last updated: January 5, 2010
Last verified: October 2009
History of Changes
  Purpose

The effect of Antibacterial Nanoparticles, Incorporated in cement, on S.mutans in the margins of provisional restorations is going to be examined clinically by using two kinds of provisional cement 1. cement with out antibacterial nanoparticles.

2.cement with small addition of IABN. after one week in the mouth the crowns are to be removed and examined for the presence and quantity of s. mutans. in vitro tests of the same has shown significant reduction in bacterial population around the provisional cement as compared to the regular cement.


Condition
Oral Rehabilitaiton
Caries
Periodontitis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Clinical Study :The Effect of Antibacterial Nanoparticles, Incorporated in Provisional Resin Based Cement, on S.Mutans in the Margins of Provisional Restorations

Resource links provided by NLM:

MedlinePlus related topics: Antibiotics
U.S. FDA Resources

Further study details as provided by Hadassah Medical Organization:

Enrollment: 10
Study Start Date: February 2007
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
patients with provisional crowns
the same patient would serve as control and test

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

hadassah dental patients

Criteria

Inclusion Criteria:

  • Patients who need provisional restorations.

Exclusion Criteria:

  • Patients who got antibacterial therapy in the past 3 months.
  • Patients using chlorhexidine gluconate.
  • Pregnant women.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00502606

Locations
Israel
Hadassah Medical Organization,
Jerusalem,, Israel
Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Principal Investigator: Michael Perez Davidi, DMD Hadassah Medical Organization
Study Director: Nir Sterer, DMD PhD Hadassah Medical Organization
Study Chair: Ervin Weiss, DMD Hadassah Medical Organization
  More Information

Additional Information:
Michael Perez Davidi  This link exits the ClinicalTrials.gov site

Publications:

Responsible Party: Ervin Weiss, Hadassah Medical Centers
ClinicalTrials.gov Identifier: NCT00502606     History of Changes
Other Study ID Numbers: 191061HMO-CTIL
Study First Received: July 16, 2007
Last Updated: January 5, 2010
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hadassah Medical Organization:
provisional restoration
antibacterial nanoparticles
cement
biofilm
bacteria
 flora
plaque
dental
prosthesis

Additional relevant MeSH terms:
Periodontitis
Periodontal Diseases
Mouth Diseases
Stomatognathic Diseases
 Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 19, 2013